首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1624423

2024 年至 2031 年疫苗佐劑市場（依產品類型、給藥途徑、疾病類型、應用及地區劃分）

Vaccine Adjuvants Market By Product, By Route of Administration, By Disease Type, Application, & Region for 2024-2031

出版日期: 2024年07月11日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

疫苗佐劑市場評估，2024-2031 年

傳染病流行的不斷增加以及對更有效疫苗接種的需求不斷增長，推動了對疫苗佐劑的需求。據 Verified Market Research 分析師稱，疫苗佐劑市場規模預計將從 2023 年的約 14.8 億美元下降至預測期內的 38.3 億美元。

全球疫苗接種工作和對抗新興傳染病的公共衛生工作正在推動疫苗佐劑市場的成長。這將使市場從 2024 年到 2031 年的複合年增長率達到 12.68%。

疫苗佐劑市場定義/概述

疫苗佐劑是添加到疫苗中的物質，用於增強對疫苗抗原的免疫反應，從本質上提高疫苗的有效性。這些佐劑模仿通常警告免疫系統感染的危險信號和炎症，增強人體對疫苗的免疫反應。這樣就可以施用更少量的抗原，從而減少需要施用的次數。

此外，疫苗佐劑的用途十分廣泛，包括針對流感、肝炎等傳染病的疫苗，以及治療癌症和過敏症的疫苗。佐劑透過提高免疫反應的有效性和持久性在疫苗開發中發揮重要作用。

是什麼推動了疫苗佐劑需求的激增？

全球傳染病和癌症疫情的不斷加劇導致對有效疫苗的需求激增。疫苗佐劑是增強疫苗免疫反應、提高疾病預防效果的重要成分。隨著公共衛生工作優先考慮疫苗接種計劃以控制和消除傳染病，對佐劑的需求可能會增加。

製藥和生技公司正在加緊研發，開發新疫苗並改進現有疫苗。這包括投資發現可以產生更強、更持久的免疫反應的新佐劑。疫苗開發創新的動力是佐劑市場的主要驅動力，各大公司都在努力提高疫苗的有效性和耐用性。

此外，世界各國政府也越來越重視疫苗接種計劃，將其視為公共衛生策略的重要組成部分。這包括對疫苗（包括佐劑疫苗）的研究、開發和分發的資金。這些措施不僅可以讓更多人獲得疫苗，還將增加對疫苗佐劑的需求，以提高疫苗效力和接種率。

哪些因素阻礙了疫苗佐劑市場擴大？

佐劑受到嚴格監管，因為它們在疫苗安全性和有效性方面發揮關鍵作用。新佐劑的批准過程漫長而複雜，通常需要進行大規模臨床試驗來確認安全性和有效性。由於擔心佐劑的潛在副作用和不良反應，其批准被推遲，使用也受到限制，成為市場成長的一大障礙。

疫苗佐劑市場競爭激烈，許多公司都在尋求創造獨特而有效的解決方案。然而，研究、測試和生產新型佐劑的成本過高，特別是對於中小型企業而言。此外，維持疫苗價格合理以供廣泛使用的需求給佐劑定價帶來壓力，影響獲利能力和研發成本。

The rising prevalence of infectious diseases, combined with the growing need for more effective vaccinations, is driving up demand for vaccine adjuvants. According to the analyst from Verified Market Research, the vaccine adjuvants market is estimated to reach a valuation of USD 3.83 Billion over the forecast subjugating aroundUSD 1.48 Billion valued in 2023.

Global immunization efforts and public health activities to address emerging infectious illnesses are driving the growth of the vaccine adjuvants market. It enables the market to grow at aCAGR of 12.68% from 2024 to 2031.

Vaccine Adjuvants Market: Definition/ Overview

Vaccine adjuvants are substances added to vaccines to boost the immune response to the vaccine's antigen, essentially increasing their efficacy. These adjuvants mimic the danger signals and inflammation that normally alert the immune system to infections, increasing the body's immunological response to the vaccine. This allows for lower quantities of the antigen to be employed, reducing the number of doses required and perhaps making the vaccine effective for a larger segment of the population.

Furthermore, vaccine adjuvants have a wide range of applications, including usage in vaccinations for infectious diseases such as influenza and hepatitis, as well as therapeutic vaccines for cancer and allergies. Adjuvants serve an important role in vaccine development by enhancing the efficacy and duration of the immune response.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Factors that Surge the Demand for the Vaccine Adjuvants Market?

The increasing prevalence of infectious diseases and cancers around the world is resulting in a surge in demand for effective vaccines. Vaccine adjuvants are essential components that boost the immune response to vaccines, increasing their effectiveness in disease prevention. As public health initiatives prioritize vaccination programmes to manage and eradicate infectious illnesses, demand for adjuvants is likely to rise.

Pharmaceutical and biotechnology companies are ramping up their research and development efforts to create new vaccines and improve existing ones. This includes investing in the discovery of new adjuvants capable of eliciting a stronger and longer-lasting immune response. This push for innovation in vaccine development is a major driver of the adjuvants market, as companies strive to improve the efficacy and durability of their vaccines.

Furthermore, governments around the world are increasingly focusing on immunization programmes as an important component of public health strategy. This includes financing for vaccine research, development, and distribution, including those using adjuvants. Such measures not only make vaccines more accessible to a larger population, but they also increase demand for vaccine adjuvants as part of attempts to improve vaccine efficacy and coverage.

What Factors Hindering the Expansion of the Vaccine Adjuvants Market?

Due to their vital role in vaccine safety and efficacy, adjuvants are regulated closely. The approval procedure for new adjuvants is lengthy and complicated, frequently requiring significant clinical trials to verify safety and efficacy. Concerns about potential side effects or adverse reactions to adjuvants cause delays in approval or limitations in use, posing a significant impediment to market growth.

The vaccine adjuvants market is fiercely competitive, with many businesses seeking to create unique and effective solutions. However, the expense of researching, testing, and manufacturing novel adjuvants is excessively expensive, especially for small businesses. Furthermore, the requirement to maintain vaccinations affordable for widespread use puts pressure on adjuvant pricing, which affects profitability and R&D expenditure.

Category-Wise Acumens

How does the Particulate Adjuvant Segment Impact the Growth of the Vaccine Adjuvants Market?

According to VMR analysis, the particulate adjuvant segment is estimated to hold the largest market share during the forecast period. Particulate adjuvants are very effective at increasing the immunological response to vaccines. They mirror the size and structure of infections, allowing the immune system to recognize and respond more effectively to vaccine antigens. This feature makes particle adjuvants particularly useful in the creation of vaccines for diseases that require a strong and long-lasting immune response to be successful.

Particulate adjuvants are highly versatile and compatible with a wide range of vaccines, including subunit, recombinant, conjugate, and inactivated vaccines. Because of their broad compatibility, they can be used in a variety of vaccines, which increases their adoption and market share. Also, their ability to be customized with specific qualities, such as size, charge, and surface modification, allows for the development of more focused and effective vaccination formulations.

Furthermore, advances in nanotechnology and materials science have considerably improved particulate adjuvant design and manufacture. These technical advancements have resulted in the production of nanoparticles and microparticles that can be carefully tailored to optimize adjuvant qualities, such as improving mucosal immunity or targeting specific immune system cells. Particulate adjuvant technology's potential uses are expanding as a result of continued research and innovation, consolidating its market dominance.

How do Commercial Applications of Vaccine Adjuvants Drive the Demand?

The commercial application segment is estimated to dominate the vaccine adjuvants market during the forecast period. Vaccination programmes have increased significantly over the world, spurred by efforts by both governments and non-governmental organizations to combat infectious illnesses and avoid epidemics. These programmes frequently necessitate huge amounts of vaccinations for general public usage, which directly increases the demand for vaccine adjuvants used in commercial vaccine manufacturing. The desire for increased immunization rates against influenza, COVID-19, HPV, and other diseases emphasizes the importance of effective vaccine adjuvants in commercial applications.

Furthermore, preventive healthcare treatments, such as vaccination for adults and the elderly, are becoming more popular to combat age-related susceptibility to infectious diseases and minimize healthcare expenses. The commercial sector has responded by creating and marketing vaccinations intended specifically for these populations, with adjuvants used to boost vaccine efficacy. This tendency helps to explain why commercial uses dominate the vaccination adjuvants market.

Country/Region-wise Acumens

Will Flourishing Pharmaceutical Sector Drive the Dominance of North America in this Market?

According to VMR analyst, North America is estimated to dominate the vaccine adjuvants market during the forecast period. North America, particularly the United States, has a well-developed healthcare system and devotes a considerable portion of its GDP to healthcare spending. This involves significant spending in R&D, vaccine manufacture, and immunisation programmes. The advanced healthcare infrastructure enables considerable vaccine research and development efforts, allowing for the rapid acceptance and integration of new vaccine adjuvants into vaccination programmes.

Furthermore, North America is home to some of the world's biggest pharmaceutical and biotechnology businesses, which play an important role in the global vaccination industry. These firms make significant investments in the research of novel vaccines and adjuvant technology, helping the area maintain its leadership in the vaccine adjuvants industry. Their efforts in innovation, together with strong pipelines for vaccine development, assure a consistent demand for vaccine adjuvant.

How will Increasing Healthcare Services in Asia Pacific Boost the Market?

The Asia Pacific region is estimated to grow at the highest CAGR during the forecast period. Asia-Pacific is characterized by its large and quickly growing population, which creates an increased demand for healthcare services, particularly immunization. As countries in this region continue to develop economically, there is a greater emphasis on strengthening healthcare infrastructure and access to preventive healthcare services like vaccination. This demographic and economic shift fuels the demand for vaccines and, by extension, vaccine adjuvants.

Furthermore, many governments in Asia-Pacific have been actively adopting and expanding national immunization programmes. These projects, which aim to increase immunization coverage in the population, frequently receive significant money and policy backing. Such government support not only enhances the vaccine market directly but also promotes the research and use of vaccine adjuvants, which are an essential component of effective vaccinations.

Competitive Landscape

The competitive landscape of the vaccine adjuvants market is dynamic and evolving, with competitors constantly striving to innovate and extend their product portfolios to suit the growing demand for more effective and less reactogenic vaccines.

Some of the prominent players operating in the vaccine adjuvants market include:

GlaxoSmithKline, Dynavax Technologies, Novavax, Croda International, Seppic, Merck KGaA, CSL Limited, InvivoGen, Pfizer, AstraZeneca, SPI Pharma, Agenus Inc, Phibro Animal Health Corporation, Vertellus, Allergy Therapeutics, Vaxine Pty Ltd, CureVac AG.

Latest Developments

In May 2021, CSL supported the State Government Budget's pledge to develop an Identity Box to encourage maritime trade and Australian medical research. The Patent Box strategy will encourage local manufacture of novel medical items while also combating the eradication of Australian intellectual property (IP) and highly skilled jobs.

1 INTRODUCTION OF GLOBAL VACCINE ADJUVANTS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL VACCINE ADJUVANTS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL VACCINE ADJUVANTS MARKET, BY PRODUCT

5.1 Overview
5.2 Pathogen
5.3 Adjuvants Emulsions
5.4 Pathogen Components
5.5 Saponin-based Adjuvants
5.6 Particulate Adjuvants
5.7 Other Adjuvants

6 GLOBAL VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

6.1 Overview
6.2 Intradermal
6.3 Subcutaneous
6.4 Others

7 GLOBAL VACCINE ADJUVANTS MARKET, BY DISEASE TYPE

7.1 Overview
7.2 Infectious Diseases
7.3 Cancer
7.4 Others

8 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION

8.1 Overview
8.2 Research Applications
8.3 Commercial Applications

9 GLOBAL VACCINE ADJUVANTS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL VACCINE ADJUVANTS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 GlaxoSmithKline
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Dynavax Technologies
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Novavax
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Croda International
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Seppic
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Merck KGaA
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 CSL Limited
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 InvivoGen
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Pfizer
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 AstraZeneca
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments